Published Date: 02 Mar 2023
A review of more than 600,000 Finnish births from 2006 to 2016 found that mothers with type 1 diabetes had more than four times as many children born with heart defects.
Read Full NewsA recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.
The newly approved inhibitor is for patients who previously received another drug of the same class.
1.
Year in Review: Multiple Myeloma
2.
Committee Recommends Canada Not Permit Euthanasia Solely for Mental Illness
3.
Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.
4.
Charting the Course: From Young Adult Leukemia Patient to Oncologist.
5.
More People Than Previously Believed Have Schizophrenia.
1.
Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives
2.
Progressive Updates in Oncology for Healthcare Excellence
3.
Bone Marrow Regenerative Capacity and Hematologic Recovery
4.
Uncovering Breast Cancer: The Power of Early Stage Ultrasound
5.
Immune Surveillance Screening for Early Cancer Risk Detection
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
2.
Navigating the Complexities of Ph Negative ALL - Part XV
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
4.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation